SunWay Biotech (1271) Fundamentals 2026 — P/E 36.9x, Revenue Analysis | SniperIQ
SunWay Biotech (1271) is a TW-listed Consumer Defensive company in Packaged Foods with a market capitalization of NT
SunWay Biotech (1271) has a market capitalization of approximately NT
SunWay Biotech's trailing twelve-month P/E ratio is 36.9x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
SunWay Biotech runs a net profit margin of 10.2%, a gross margin of 56.4%, and an operating margin of 10.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
SunWay Biotech reported revenue of NT$993M for fiscal year 2025, with net income of NT
SunWay Biotech offers a trailing dividend yield of about 2.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
SunWay Biotech carries a debt-to-equity ratio of 0.27x and a current ratio of 1.62x, with a market beta of -0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SunWay Biotech (1271) the key facts are: market cap NT
Get SunWay Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.